Drug Patents owned by Kadmon Pharms Llc
1. List of Rezurock drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Oct, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US11311541 | KADMON PHARMS LLC | Treatment of GVHD |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity (ODE) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 2025-07-16
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chr...
Dosage: TABLET;ORAL
REZUROCK family patents
23
United States
6
China
4
Japan
3
Canada
3
European Union
2
Spain
2
EA
1
South Africa
1
Denmark
1
Mexico
1
Australia
1
Slovenia
1
Lithuania
1
Hungary
1
Norway
1
Costa Rica
1
Singapore
1
Croatia
1
Brazil
1
Portugal
1
Korea, Republic of
1
Poland
1
RS
1
Ecuador
1
Georgia
1
Ukraine
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic